In the fall of 1999, a young chemical engineer named Todd Zion left his job at Eastman Kodak to enroll in the Ph.D. program at the Massachusetts Institute of Technology.
While looking for a subject to research, Zion noticed a grant proposal, never funded, that another graduate student had written on the subject of drug delivery. One possibility mentioned in the proposal was the development of a kind of insulin that would automatically respond to changes in blood-sugar levels, becoming active only when needed to maintain healthy levels around the clock. If it worked, the sugar-sensitive version could transform the lives of the six million people with diabetes in the United States who use insulin. No longer would they have to test their blood-sugar levels multiple times per day and try to calculate how much insulin to take. The self-regulating insulin would curtail high sugar levels, which raise the risk of long-term complications, and eradicate, or at least reduce, the most dangerous short-term complication: hypoglycemia, when sugar levels fall so low that they can cause confusion, unconsciousness, seizures and even death.
“I thought, Wow, that is a really neat area in which to do research,” Zion told me. Other researchers had been trying for 20 years to make insulin work only when needed. The first to publish a study were the scientists Michael Brownlee and Anthony Cerami, who in 1979 embedded a sugar-encrusted form of insulin in a mesh pouch with a sugar-loving protein called lectin. The idea was that when blood-sugar levels were elevated, the lectin would bind to the sugar in the blood and allow the insulin to leak out; when sugar levels were normal, the lectin would bind to the sugar-encrusted insulin, keeping it inside the pouch. But the system was impractical, because the pouch would need to be implanted under the skin and periodically refilled. And the lectin, derived from the jack-bean plant, was toxic.
In his first three years at M.I.T., Zion used nanoscale molecular engineering to create an insulin-lectin gel that could be injected without the need for an implanted pouch, while also rejiggering the lectin to make it less toxic. “It worked great visually,” he said. When the gel was placed in a sugar solution, “you could see the outer edge getting clear and dissolving . . . almost like an ice cube melting in water.”
The problem was that, no matter how hard he tried to manipulate the gel, the insulin either leaked out too easily, even when sugar levels were low, or not easily enough, when sugar levels were high.
Zion knew there was another approach: changing the insulin molecule itself, to make it sensitive to blood-sugar levels directly. But, he said, “almost everyone in the field of drug discovery believed that you should never, ever change the insulin molecule. . . . From a regulatory point of view, as soon as you manipulate the molecule, you’ve created a new drug. It doesn’t matter if you’ve attached a single atom to it.” Doing so, he knew, would require years of clinical trials in preparation for a new-drug application submission to the F.D.A. “That’s the only reason people were afraid.”
Zion’s trick was to attach a chemical arm — a short chain of sugars — directly onto the insulin molecule. (Attaching sugar to insulin? “Yes, it is a bit ironic,” he concedes.) The beauty of this approach is that it permits the insulin to latch directly onto the sugar-loving lectin in the gel — but only as needed. When blood-sugar levels are high, the lectin hooks up with any sugar floating freely from the blood, allowing the insulin molecule to do its normal job of connecting with insulin receptors on the surface of cells. (That is how insulin lowers blood-sugar levels, by merging with a cell’s insulin receptor and unlocking the cell membrane to allow sugar in.) When the sugar gets swallowed up by cells, lowering levels in the blood, the only remaining sweet for the lectin to attach to is the altered insulin’s sugar arm. Handcuffed to the lectin, the insulin can’t bind to insulin receptors. And so the insulin stops working to lower blood-sugar levels precisely when it’s no longer needed, because its sugar chain is held hostage by the lectin.
Zion called his new chemical creation smart insulin. In 2003, after testing it in rats, he won M.I.T.’s annual Entrepreneurship Competition. With the $30,000 prize money, he started a company called SmartCells and tried to see if he could make it work well enough to test it in humans.
The Latest on: Inventing drugs
via Google News
The Latest on: Inventing drugs
- Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeuticson May 28, 2022 at 2:37 am
“We see opportunities with GLP’s, orphan indications, and the extension of major categories of biologic drugs, which have the potential for oral delivery through Entera’s platform. Concurrently, we ...
- When a machine invents things for humanity, who gets the patent?on May 27, 2022 at 6:53 am
The day is coming—some say has already arrived—when artificial intelligence starts to invent things that its human creators could not. But our laws are lagging behind this technology, UNSW experts say ...
- InventHelp Inventors Develop Therapeutic Product to Relieve Migraines (FJK-142)on May 26, 2022 at 11:51 am
PITTSBURGH, May 26, 2022 /PRNewswire/ -- "We wanted to create a therapeutic product to help reduce the pain associated with standard or migraine headaches," said one of two inventors, from Lauderhill, ...
- Owen A. O'Connor, M.D., Ph.D., is recognized by Continental Who's Whoon May 26, 2022 at 10:40 am
Owen A. O'Connor, M.D., Ph.D., is being recognized by Continental Who's Who as a Distinguished Medical Oncologist for inventing and developing many drugs for the treatment of blood cancers, and in ...
- Congress and the White House Can Provide Relief from High Oil and Drug Prices | Opinionon May 23, 2022 at 5:00 am
Drugs aren't expensive because they cost so much to make, or even because it takes a lot of money to invent a new pharmaceutical. They are expensive because Big Pharma benefits from monopoly ...
- James Allison: ‘The cost of some cancer drugs is crazy. There’s no relationship to the cost of making the drug anymore’on May 20, 2022 at 6:56 pm
The American researcher won the Nobel Prize in Medicine for inventing immunotherapy. Now he is looking for a way to extend the treatment’s effectiveness to fatal tumors ...
- Fake heiress behind Inventing Anna appears from jail virtually at her solo art showon May 20, 2022 at 7:21 am
Convicted fraudster Anna Delvey was able to attend an exhibition of her art collection ‘worth £400,935’ from behind bars. The infamous con-artist has become known all over the world, after the Netflix ...
- Inventing Anna got it right. Anna Delvey did in fact know Billy McFarland and Martin Shkreli.on May 19, 2022 at 11:13 am
Anna Sorokin, better known as Anna Delvey, once rubbed shoulders with New York’s City’s elite – including Billy McFarland and Martin Shkreli. Netflix’s new miniseries documents the fake German heiress ...
- Contact lens that can release drug could be used to treat glaucomaon May 17, 2022 at 7:25 am
Invention can deliver medication after detecting pressure in the eye from fluid buildup, scientists say ...
- Rapid ‘barcode’ sensor can screen for drug-resistant bacteriaon May 17, 2022 at 12:54 am
A Hong Kong Baptist University (HKBU)-led research team has developed a novel cell sensor with a barcode-like micro-channel structure that enables rapid and low-cost screening of drug-resistant ...
via Bing News